ASX:MSBBiotechs
Mesoblast (ASX:MSB) Valuation After New Ryoncil Data And Planned Adult Pivotal Trial
Mesoblast (ASX:MSB) has presented new clinical data for its lead therapy Ryoncil to investors, highlighting high survival outcomes in steroid refractory acute graft versus host disease across both pediatric and adult patients.
See our latest analysis for Mesoblast.
The new Ryoncil data lands after a mixed period for Mesoblast shares, with a 10.36% 90 day share price return contrasting with an 11.55% year to date share price decline and a very large 3 year total shareholder return. This...